GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viridian Therapeutics Inc (LTS:0K1R) » Definitions » YoY EPS Growth

Viridian Therapeutics (LTS:0K1R) YoY EPS Growth : -47.46% (As of Mar. 2025)


View and export this data going back to 2018. Start your Free Trial

What is Viridian Therapeutics YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Viridian Therapeutics's YoY EPS Growth for the quarter that ended in Mar. 2025 was -47.46%.

Viridian Therapeutics's Earnings per Share (Diluted) for the three months ended in Mar. 2025 was $-0.87.


Viridian Therapeutics YoY EPS Growth Historical Data

The historical data trend for Viridian Therapeutics's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viridian Therapeutics YoY EPS Growth Chart

Viridian Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -55.34 78.61 59.31 -44.28 21.48

Viridian Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 63.35 19.69 -5.50 40.00 -47.46

Viridian Therapeutics YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Viridian Therapeutics's YoY EPS Growth for the fiscal year that ended in Dec. 2024 is calculated as:

YoY EPS Growth (A: Dec. 2024 )
=(Earnings per Share (Diluted) (A: Dec. 2024 )-Earnings per Share (Diluted) (A: Dec. 2023 ))/ | Earnings per Share (Diluted) (A: Dec. 2023 ) |
=(-3.07--3.91)/ | -3.91 |
=21.48 %

Viridian Therapeutics's YoY EPS Growth for the quarter that ended in Mar. 2025 is calculated as:

YoY EPS Growth (Q: Mar. 2025 )
=(Earnings per Share (Diluted) (Q: Mar. 2025 )-Earnings per Share (Diluted) (Q: Mar. 2024 )) / | Earnings per Share (Diluted) (Q: Mar. 2024 )) |
=(-0.87--0.59)/ | -0.59 |
=-47.46 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Viridian Therapeutics YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Viridian Therapeutics's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Viridian Therapeutics Business Description

Traded in Other Exchanges
Address
221 Crescent Street, Suite 103A, Waltham, MA, USA, 02453
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).

Viridian Therapeutics Headlines

No Headlines